Payment overview · 2025
General Payments
$478.45
27 reported records · 10 companies
Healthcare provider profile · identity verified
Michael T Wayt, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GLEN DALE, WV · NPI 1639164684
Verified facts
What the public records show
CMS Open Payments records show Michael T Wayt, M.D. received $478.45 in general payments during 2025 across 27 reported records.
AstraZeneca Pharmaceuticals LP accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Paxlovid.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $145.24 | 30.4% | 8 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $73.47 | 15.4% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $64.99 | 13.6% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $59.47 | 12.4% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $39.29 | 8.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.14 | 4.8% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.12 | 4.4% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $18.52 | 3.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.95 | 3.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.26 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $478.45 | 27 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRILINTA Normalized: brilinta |
Drug | AstraZeneca Pharmaceuticals LP | $127.64 | 7 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $73.47 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $64.99 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $59.47 | 3 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Optinose US, Inc., Paratek Pharmaceuticals, Inc. | $39.64 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $39.29 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.14 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 180 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 25 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
180 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
220 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 824 | 208 |
| Atorvastatin Calcium | Atorvastatin Calcium | 820 | 230 |
| Levothyroxine Sodium | Levothyroxine Sodium | 782 | 156 |
| Omeprazole | Omeprazole | 635 | 157 |
| Lisinopril | Lisinopril | 618 | 176 |
| Metformin Hcl | Metformin Hcl | 482 | 117 |
| Metoprolol Succinate | Metoprolol Succinate | 442 | 124 |
| Losartan Potassium | Losartan Potassium | 392 | 104 |
| Tamsulosin Hcl | Tamsulosin Hcl | 375 | 103 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 374 | 78 |
| Potassium Chloride | Potassium Chloride | 355 | 101 |
| Gabapentin | Gabapentin | 324 | 85 |
| Furosemide | Furosemide | 312 | 93 |
| Simvastatin | Simvastatin | 308 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 300 | 90 |
| Alprazolam | Alprazolam | 299 | 52 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 299 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 291 | 91 |
| Atenolol | Atenolol | 222 | 58 |
| Pravastatin Sodium | Pravastatin Sodium | 222 | 60 |
| Eliquis | Apixaban | 220 | 43 |
| Sertraline Hcl | Sertraline Hcl | 215 | 57 |
| Mounjaro | Tirzepatide | 197 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 190 | 34 |
| Montelukast Sodium | Montelukast Sodium | 180 | 39 |
| Ozempic | Semaglutide | 180 | 33 |
| Tramadol Hcl | Tramadol Hcl | 180 | 63 |
| Trazodone Hcl | Trazodone Hcl | 179 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 172 | 36 |
| Azithromycin | Azithromycin | 168 | 137 |
| Valsartan | Valsartan | 165 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 45 |
| Clopidogrel | Clopidogrel Bisulfate | 154 | 38 |
| Allopurinol | Allopurinol | 140 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 140 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 140 | 35 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 134 | 35 |
| Lorazepam | Lorazepam | 127 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 126 | 18 |
| Celecoxib | Celecoxib | 121 | 31 |
| Famotidine | Famotidine | 120 | 34 |
| Memantine Hcl | Memantine Hcl | 117 | 16 |
| Meloxicam | Meloxicam | 111 | 37 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 111 | 81 |
| Methylprednisolone | Methylprednisolone | 110 | 92 |
| Donepezil Hcl | Donepezil Hcl | 109 | 31 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 26 |
| Synthroid | Levothyroxine Sodium | 107 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 104 | 27 |
| Carvedilol | Carvedilol | 102 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 100 | 39 |
| Amoxicillin | Amoxicillin | 100 | 81 |
| Oxycodone Hcl | Oxycodone Hcl | 96 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 93 | 22 |
| Glipizide | Glipizide | 79 | 25 |
| Glimepiride | Glimepiride | 76 | 22 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 15 |
| Ezetimibe | Ezetimibe | 73 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 21 |
| Finasteride | Finasteride | 72 | 19 |
| Buspirone Hcl | Buspirone Hcl | 71 | 19 |
| Ibuprofen | Ibuprofen | 70 | 23 |
| Warfarin Sodium | Warfarin Sodium | 70 | 15 |
| Prednisone | Prednisone | 69 | 45 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 20 |
| Alendronate Sodium | Alendronate Sodium | 65 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 65 | 47 |
| Amitriptyline Hcl | Amitriptyline Hcl | 62 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 62 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 12 |
| Pregabalin | Pregabalin | 56 | 13 |
| Clonazepam | Clonazepam | 55 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 16 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 53 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 13 |
| Metformin Hcl Er | Metformin Hcl | 47 | 15 |
| Chlorthalidone | Chlorthalidone | 46 | 16 |
| Jardiance | Empagliflozin | 46 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 46 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 12 |
| Glipizide Er | Glipizide | 43 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 43 | 13 |
| Mirtazapine | Mirtazapine | 42 | 15 |
| Aripiprazole | Aripiprazole | 41 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 41 | suppressed |
| Methocarbamol | Methocarbamol | 40 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | 12 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 38 | suppressed |
| Bupropion Xl | Bupropion Hcl | 38 | 11 |
| Dutasteride | Dutasteride | 38 | 11 |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 27 |
| Lovastatin | Lovastatin | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 36 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 36 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 36 | suppressed |
| Cefdinir | Cefdinir | 35 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 19 |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Irbesartan | Irbesartan | 34 | suppressed |
| Temazepam | Temazepam | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Nystatin | Nystatin | 33 | 18 |
| Ranolazine Er | Ranolazine | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 32 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 27 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 31 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 28 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 16 |
| Estradiol | Estradiol | 24 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 18 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 19 | suppressed |
| Armour Thyroid | Thyroid,pork | 19 | suppressed |
| Dofetilide | Dofetilide | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 17 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Dulera | Mometasone/Formoterol | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Niacin Er | Niacin | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
| Xtampza Er | Oxycodone Myristate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $478.45 · 27 records | AstraZeneca Pharmaceuticals LP | BRILINTA, Cologuard Collection Kit, FARXIGA, NURTEC ODT, NUZYRA, Ozempic, PAXLOVID, REXULTI, VOQUEZNA, Veozah, XHANCE, ZORYVE | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error